Sonn-Segev, Adar
Belacic, Katarina https://orcid.org/0000-0002-4024-5497
Bodrug, Tatyana
Young, Gavin
VanderLinden, Ryan T.
Schulman, Brenda A. https://orcid.org/0000-0002-3083-1126
Schimpf, Johannes
Friedrich, Thorsten https://orcid.org/0000-0002-0813-7883
Dip, Phat Vinh https://orcid.org/0000-0002-1535-9644
Schwartz, Thomas U. https://orcid.org/0000-0001-8012-1512
Bauer, Benedikt
Peters, Jan-Michael
Struwe, Weston B.
Benesch, Justin L. P. https://orcid.org/0000-0002-1507-3742
Brown, Nicholas G. https://orcid.org/0000-0002-6141-0164
Haselbach, David https://orcid.org/0000-0002-5276-5633
Kukura, Philipp https://orcid.org/0000-0003-0136-7704
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (PHOTOMASS 819593)
EC | Horizon 2020 Framework Programme (693949)
Foundation for the National Institutes of Health (T32GM00857)
Foundation for the National Institutes of Health (R37GM065930)
Foundation for the National Institutes of Health (P30CA021765)
Foundation for the National Institutes of Health (R01GM77537)
Foundation for the National Institutes of Health (R35GM128855)
Foundation for the National Institutes of Health (P30AI050410)
National Science Foundation (DGE-1650116)
Howard Hughes Medical Institute
Deutsche Forschungsgemeinschaft (278002225/RTG 2202)
Deutsche Forschungsgemeinschaft (FR 1140/11-2)
European Molecular Biology Organization
Human Frontier Science Program (RGP0057/2018)
Boehringer Ingelheim
Österreichische Forschungsförderungsgesellschaft (FFG-852936)
UNC | UNC-Chapel Hill | Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Article History
Received: 20 January 2020
Accepted: 12 March 2020
First Online: 14 April 2020
Competing interests
: P.K. is a founder, director and shareholder in Refeyn Ltd. W.B.S. is a consultant and shareholder in Refeyn Ltd. G.Y. and J.L.P.B. are founders, consultants and shareholders in Refeyn Ltd. All other authors declare no competing interest.